Largest Life Science Venture Transactions in 2022

Third Harmonic Bio is a clinical stage bio technology company developing an oral KIT inhibitor therapy for allergic autoimmune disorders. Third Harmonic Bio was founded in 2019 and is based in San Francisco, California.

General Atlantic
Investor
Growth Capital Firm
New York, New York
www.generalatlantic.com

Ultima Genomics focuses on developing next-generation genome sequencing technology for the high-volume research and clinical markets. Ultima Genomics was founded in 2016 and is based in Fremont, California.

General Atlantic
Investor
Growth Capital Firm
New York, New York
www.generalatlantic.com

Elucidata is a life sciences MLOps company for the future that transforms biological discovery by integrating different forms of biomedical data. Elucidata was founded in 2015 and is based in San Francisco, California.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Tubulis develops next-generation antibody–drug conjugates by combining novel protein-linking technologies with disease-tailored payloads. The company creates highly stable ADCs designed to improve therapeutic precision and safety. Tubulis was founded in 2018 and is based in Planegg-Martinsried, Germany.

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

TargED is a private biotechnology company focused on developing improved treatments for thrombotic diseases. TargED was founded in 2018 and is based in Utrecht, Netherlands.

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

ImmunOs Therapeutics is a preclinical stage biotech company which develops a proprietary target discovery platform allowing to discover novel molecules inspired by HLA molecules and physiological immunosuppressive molecules. ImmunOs Therapeutics was founded in 2014 and is based in Schlieren, Switzerland.

GIMV
Investor
Private Equity Firm
Antwerp, Belgium
www.gimv.com

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. SpliceBio is based in Barcelona, Spain.

Gilde Healthcare
Investor
Private Equity Firm
Utrecht, Netherlands
www.gildehealthcare.com

Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the company is initially developing for the treatment of patients with uncontrolled hypertension. Mineralys was founded in 2019 and is based in Radnor, Pennsylvania.

Adams Street Partners
Investor
Asset Manager
Chicago, Illinois
www.adamsstreetpartners.com

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

HBM Partners
Investor
Private Equity Firm
Zug, Switzerland
www.hbmpartners.com

Capstan Therapeutics is developing a targeted delivery platform and therapeutics to reprogram immune cells in vivo for a broad range of disease categories. Capstan was founded in 2021 and is based in San Diego, California.

Polaris Partners
Investor
Growth Capital Firm
Boston, Massachusetts
www.polarispartners.com

Satellite Bio is developing satellite livers to bridge or replace liver transplantations. Satellite Bio was founded in 2019 and is based in Cambridge, Massachusetts.

Polaris Partners
Investor
Growth Capital Firm
Boston, Massachusetts
www.polarispartners.com

Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Seismic Therapeutic is based in Cambridge, Massachusetts.

Polaris Partners
Investor
Growth Capital Firm
Boston, Massachusetts
www.polarispartners.com

Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer. Tessa Therapeutics is based in Singapore.

Polaris Partners
Investor
Growth Capital Firm
Boston, Massachusetts
www.polarispartners.com

TRex Bio is identifying and advancing a pipeline of medicines for debilitating inflammatory conditions by targeting the underlying dysregulation that drives disease. TRex Bio was founded in 2018 and is based in San Francisco, California.

Polaris Partners
Investor
Growth Capital Firm
Boston, Massachusetts
www.polarispartners.com

Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Vernal Biosciences is based in Colchester, Vermont.

Ampersand Capital Partners
Investor
Growth Capital Firm
Wellesley, Massachusetts
www.ampersandcapital.com

Enhanc3D Genomics is a functional genomics company, unlocking the full potential of the human 3D genome to transform therapeutic development. Enhanc3D Genomics is based in Cambridge, United Kingdom.

BGF
Investor
Growth Capital Firm
London, United Kingdom
www.bgf.co.uk

Alternative Bio is a biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes. Alternative Bio is based in Singapore.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com